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Background: Stem cell therapy provides a potential opportunity to treat patients with heart disease given the limited regenerative capacity 
of the heart. However, no reliable imaging technique exists to longitudinally assess their engraftment after transplantation. This study 
sought to determine the utility of magnetic resonance imaging (MRI) in tracking iron-oxide (Feraheme) labeled human embryonic stem cell-
derived cardiovascular cells (hESC-CPCs) that were transplanted in pig hearts.
methods: hESC-CPCs, at different stages of differentiation, were labeled for 24 hours with varying Feraheme concentrations (50ug/ml, 
100ug/ml, 200ug/ml, 300ug/ml). Differentiation efficiency and cell viability were determined by flow cytometry. Optimal labeling conditions 
were determined and used for ex vivo and in vivo imaging experiments. Feraheme-labeled hESC-CPCs were transplanted by open surgical 
methods in the left ventricle free walls of un-injured pigs hearts and comprehensive T2* weighted images were obtained immediately after 
transplantation and 40 days later prior to termination.
results: Labeling hESC-CPCs with 300ug/ml of Feraheme at day 0 of cardiac differentiation offered optimal cell viability and adequate 
signal intensity with MRI (R2*value: 2.3+/-.19 n=3). Under these labeling conditions, hESC-CPCs differentiated towards definitive cardiac 
cell types both in vitro and in vivo. Localization, dispersion and movement of labeled cells could be effectively imaged and tracked at 
days 0 and 40 by MRI. Tissue analysis at the end of the study revealed that the majority of the transplanted cells were not retained in the 
myocardium, but the grafted cells showed differentiation towards all definitive cardiac cell types.
conclusion:  Under described conditions, Feraheme can be used as a long term, differentiation-neutral hESC-CPCs labeling agent to 
track transplanted cells in vivo by MRI imaging.
